<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552578</url>
  </required_header>
  <id_info>
    <org_study_id>FMD0400907A</org_study_id>
    <nct_id>NCT00552578</nct_id>
  </id_info>
  <brief_title>Buprenorphine as a Treatment in Opiate Dependent Pain Patients</brief_title>
  <official_title>A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if different doses of buprenorphine (either tapering
      doses or steady doses) are effective in managing chronic, non-cancer pain in individuals who
      also are addicted to opiate pain medicines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context: Some individuals have two conditions: 1) a well-documented pain disorder and 2)
      clear evidence of a substance use disorder with opiate dependency. It is not known how to
      manage these patients. In addition to other modalities for the treatment of chronic pain,
      combination tablets of buprenorphine/naloxone (Suboxone) may be helpful.

      Objective: The objective of this study is to determine if the addition of pharmacotherapy
      with Suboxone to usual care would improve clinical outcome relative to usual care alone.

      Design: Randomized control trial.

      Setting: The study will be conducted in the out-patient clinics of a tertiary-care teaching
      hospital.

      Participants: The participants will be those who have: 1) a well-documented pain disorder and
      2) clear evidence of a substance use disorder with opiate dependency.

      Baseline data collected: Data collected at baseline will include (with examples):
      demographics (age, gender, race), substance use history (type of substances used, duration of
      use, routes of abuse), type of pain disorder (previous traumatic injury, musculoskeletal,
      neuropathic), co-existing medical problems (seizures, hepatitis C), prior injuries
      (accidents, interpersonal violence), prior mental health problems (prior treatment,
      diagnoses), prior substance abuse treatment (outpatient, inpatient), socioeconomic variables
      (educational level, occupation, employment history), criminal history (number of arrests and
      convictions, total amount of time spent in jail or prison), family history (first degree
      relatives with substance use disorders) and scores on psychometric testing (ASI).

      Outcome data: Three main outcome variables will be examined relapse to substance use (as
      documented by toxicology), quality of life, and successful participation in the pain
      management program for six months, which included the completion of the study buprenorphine
      treatment protocols.

      Data analyses: Outcome variables will be compared between the two groups using t-tests or
      chi-square tests as appropriate. A Kaplan-Myer survival analysis will be used to describe
      participant participation. Predictors of poor outcomes will be identified using a
      case-control design in which those with poor outcomes (the &quot;cases&quot;) will be compared to those
      with successful outcomes (the &quot;controls&quot;) using multivariate techniques (logistic
      regression).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    &quot;Tapering doses&quot; protocol arm was not effective for treatment retention outcome.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse to Substance Abuse</measure>
    <time_frame>Six months</time_frame>
    <description>Relapse to substance abuse (yes/no) was determined by participant self-report or by a positive urine toxicology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Better Overall Quality of Life at Six Months as Compared to Baseline.</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Qualitative measure (better/no change/worse) of participant's perception of overall quality of life related to assigned study protocol arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Retention.</measure>
    <time_frame>Six months</time_frame>
    <description>&quot;Treatment retention&quot; was defined as the completion of the buprenorphine dosing protocol (i.e., tapering doses vs. steady doses).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Opiate Addiction</condition>
  <condition>Refractory Pain</condition>
  <arm_group>
    <arm_group_label>Tapering doses of buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steady doses of buprenrophine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine/naloxone</intervention_name>
    <description>sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)</description>
    <arm_group_label>Tapering doses of buprenorphine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine/naloxone</intervention_name>
    <description>sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response</description>
    <arm_group_label>Steady doses of buprenrophine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic refractory pain

          -  Clinical diagnosis of opiate dependency

        Exclusion Criteria:

          -  unable to pay for medication

          -  enrolled in a methadone maintenance program

          -  homelessness

          -  major mental illness

          -  pregnant women

          -  prisoners

          -  terminal cancer pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard D Blondell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erie County Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. J Addict Med. 2010 Sep;4(3):140-6. doi: 10.1097/ADM.0b013e3181ba895d.</citation>
    <PMID>20959867</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2007</study_first_submitted>
  <study_first_submitted_qc>November 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <results_first_submitted>January 21, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>February 14, 2011</last_update_submitted>
  <last_update_submitted_qc>February 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Richard D. Blondell</name_title>
    <organization>SUNYBuffalo, Dept Family Medicine</organization>
  </responsible_party>
  <keyword>drug dependence</keyword>
  <keyword>substance abuse</keyword>
  <keyword>substance use disorders</keyword>
  <keyword>myofascial pain syndrome</keyword>
  <keyword>neuralgia</keyword>
  <keyword>back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 participants recruited Dec 2007 to Apr 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tapering Doses of Buprenorphine</title>
          <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
        </group>
        <group group_id="P2">
          <title>Steady Dose of Buprenorphine</title>
          <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapering Doses of Buprenorphine</title>
          <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
        </group>
        <group group_id="B2">
          <title>Steady Dose of Buprenorphine</title>
          <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="6"/>
                    <measurement group_id="B2" value="46" spread="15"/>
                    <measurement group_id="B3" value="45" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse to Substance Abuse</title>
        <description>Relapse to substance abuse (yes/no) was determined by participant self-report or by a positive urine toxicology.</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapering Doses of Buprenorphine</title>
            <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
          </group>
          <group group_id="O2">
            <title>Steady Dose of Buprenorphine</title>
            <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse to Substance Abuse</title>
          <description>Relapse to substance abuse (yes/no) was determined by participant self-report or by a positive urine toxicology.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent to treat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0098</ci_lower_limit>
            <ci_upper_limit>2.8215</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Better Overall Quality of Life at Six Months as Compared to Baseline.</title>
        <description>Qualitative measure (better/no change/worse) of participant's perception of overall quality of life related to assigned study protocol arm.</description>
        <time_frame>Baseline and six months</time_frame>
        <population>Reported value (number) was the number who reported a &quot;better&quot; overall quality-of-life to the question: &quot;How would you describe your overall level of function now as compared to the time right before you started the study?&quot; Responses were recorded as: &quot;better,&quot; &quot;no change,&quot; or &quot;worse.&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Tapering Doses of Buprenorphine</title>
            <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
          </group>
          <group group_id="O2">
            <title>Steady Dose of Buprenorphine</title>
            <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Better Overall Quality of Life at Six Months as Compared to Baseline.</title>
          <description>Qualitative measure (better/no change/worse) of participant's perception of overall quality of life related to assigned study protocol arm.</description>
          <population>Reported value (number) was the number who reported a &quot;better&quot; overall quality-of-life to the question: &quot;How would you describe your overall level of function now as compared to the time right before you started the study?&quot; Responses were recorded as: &quot;better,&quot; &quot;no change,&quot; or &quot;worse.&quot;</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Retention.</title>
        <description>&quot;Treatment retention&quot; was defined as the completion of the buprenorphine dosing protocol (i.e., tapering doses vs. steady doses).</description>
        <time_frame>Six months</time_frame>
        <population>Analysis was intent-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapering Doses of Buprenorphine</title>
            <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
          </group>
          <group group_id="O2">
            <title>Steady Dose of Buprenorphine</title>
            <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Retention.</title>
          <description>&quot;Treatment retention&quot; was defined as the completion of the buprenorphine dosing protocol (i.e., tapering doses vs. steady doses).</description>
          <population>Analysis was intent-to-treat.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test was used and tested the hypothesis that neither group would be more likely to complete the study protocol.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>No adjustment</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tapering Doses of Buprenorphine</title>
          <description>Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.</description>
        </group>
        <group group_id="E2">
          <title>Steady Dose of Buprenorphine</title>
          <description>Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R Blondell</name_or_title>
      <organization>SUNY Buffalo</organization>
      <phone>716-898-4971</phone>
      <email>blondell@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

